842136-27-0

Basic information

• Product Name: 5-bromo-2,4-dimethylbenzoic acid
• Synonyms: 5-bromo-2,4-dimethylbenzoic acid
• CAS NO: 842136-27-0
• Molecular Formula: C₉H₉BrO₂
• Molecular Weight: 229.07056
• Mol File: 842136-27-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5-bromo-2,4-dimethylbenzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 5-bromo-2,4-dimethylbenzoic acid(842136-27-0)
• EPA Substance Registry System: 5-bromo-2,4-dimethylbenzoic acid(842136-27-0)

Safety Data

• Hazardous Substances Data: 842136-27-0(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
5-bromo-2,4-dimethylbenzoic acid is used as a building block for the synthesis of various organic compounds. Its unique structural characteristics allow it to be a key component in the creation of new molecules with potential applications in various industries.
Used in Pharmaceutical Research:
5-bromo-2,4-dimethylbenzoic acid is utilized as a starting material in the development of pharmaceuticals. Its potential applications in the creation of new drugs make it an important compound in the field of medicinal chemistry.
Used in Agrochemical Development:
5-bromo-2,4-dimethylbenzoic acid is also used in the development of agrochemicals. Its properties and reactivity make it a promising candidate for the synthesis of new agrochemicals with potential applications in agriculture.
Used as a Reagent in Chemical Reactions:
5-bromo-2,4-dimethylbenzoic acid serves as a reagent in various chemical reactions. Its ability to participate in different types of reactions makes it a useful tool in the synthesis of other compounds.
Used as a Reference Standard for Analytical Assays:
5-bromo-2,4-dimethylbenzoic acid is employed as a reference standard in analytical assays. Its well-defined structure and properties make it an ideal compound for calibration and quality control purposes in various analytical techniques.

Upstream product

• 89-74-7 2,4-dimethylacetophenone. 
• 2623-45-2 2-chloro-1-(2,4-dimethyl-phenyl)-ethanone 
• 5469-19-2 1-bromo-2,4,5-trimethylbenzene 
• 7697-37-2 nitric acid 
• 110-05-4 di-tert-butyl peroxide 
• 7697-26-9 3-bromo-4-methylbenzoic acid 
• 152849-72-4 methyl 3-bromo-2,4-dimethylbenzoate 
• 611-01-8 2,4-dimethyl-benzoic acid 
• 824-55-5 2,4-dimethyl-benzyl chloride 
• 854693-48-4 5-bromo-2,4-dimethyl-benzyl chloride 
• 95-63-6 1,2,4-Trimethylbenzene 
• 383176-10-1 5-bromo-2,4-dimethylbenzaldehyde 
• 124-38-9 carbon dioxide 
• 615-87-2 1,5-dibromo-2,4-dimethylbenzene 

Downstream Products

• 53379-60-5 1-(5-bromo-2,4-dimethylphenyl)ethanone 

Relevant articles and documents

2-OXO-2,3-DIHYDRO-1H-IMIDAZO[4,5-B]PYRIDIN-6-YL)-4-METHYLBENZAMIDE DERIVATIVES AND SIMILAR COMPOUNDS AS RIPK2 INHIBITORS FOR TREATING E.G. AUTOIMMUNE DISEASES

Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein α, β, R2, R3, R4, R5, R8, R9, X1, X6, and X7 are defined in the specification. The compounds of formula 1 are receptor-interacting protein kinase 2 (RIPK2) inhibitors for treating e.g. type I hypersensitivity reactions, autoimmune diseases, inflammatory disorders, cancer and non-malignant proliferative disorders, such as e.g. allergic rhinitis, asthma, atopic dermatitis, rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, lupus nephritis, psoriasis, immune thrombocytopenic purpura, inflammatory bowel disease, chronic obstructive pulmonary disease, Sjogren's syndrome, ankylosing spondylitis, Behcet's disease, graft versus host disease, pemphigus vulgaris, idiopathic plasmacytic lymphadenopathy, atherosclerosis, myocardial infarction and thrombosis. The present description discloses the preparation of exemplary compounds as well as pharmacological data thereof (e.g. pages 107 to 208; examples 1 to 109; table 1). An exemplary compound is e.g. N-cyclopropyl-2-fluoro-5-(l-(2-fluoroethyl)-3-(l-hydroxy-2-methylpropan-2-yl)-2-oxo-2,3-dihydro-lH-imidazo[4,5-b]pyridin-6-yl)-4-methylbenzamide (example 1).

Preparation method for o-tolylacetic acid aryl formic acid derivative

The invention discloses a preparation method for an o-tolylacetic acid aryl formic acid derivative. According to the method, new C-C bonds can be formed, the organic o-tolylacetic acid aryl formic acid derivative is obtained, the good functional group tolerance is achieved, and the o-tolylacetic acid aryl formic acid derivative which cannot be easily obtained by adopting other methods can be synthesized; according to the method, adopted raw materials are easy to obtain, the yield is high, the reaction conditions are mild, the substrate range is wide, and after-treatment is simple and green.

Palladium-Catalyzed ortho-C-H Methylation of Benzoic Acids

A palladium-catalyzed methylation of C-H bonds of benzoic acids with di-tert-butyl peroxide as the methylating reagent under an external oxidant and ligand-free conditions has been achieved. The reaction is found to be directed by a weakly coordinating carboxyl group, offering a facile route for the synthesis of highly functionalized ortho-methyl benzoic acids.

PHENYL mTORC INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

NAPHTHYRIDINES AS INHIBITORS OF HPK1

Naphthyridine compounds and their use as inhibitors of HPK1 are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the naphthyridine compounds.

SUBSTITUTED BENZENE COMPOUNDS

The present invention relates to substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.

INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL

This invention relates to compounds having structural Formula I: and pharmaceutically acceptable salts thereof which are inhibitors of the Renal Outer Medullary Potassium (ROMK) channel (Kir1.1). The compounds of Formula I are useful as diuretics and natriuretics and therefore are useful for the therapy and prophylaxis of disorders resulting from excessive salt and water retention, including cardiovascular diseases such as hypertension and chronic and acute heart failure

Synthesis of Sterically Hindered 1,3-Connected Polyarylmethanes

Sterically hindered 1,3-connected polyarylmethanes were prepared by repetitive additions of aryllithiums to carbonyl compounds.Synthetic routes with various degree of convergence were used.Variable temperature NMR spectroscopy, in conjunction with other t